Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PGK1 | P00558 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20940075 | 0.95 | KMT2A (0.45) | KMT2AALOX5RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL21790412 | 0.95 | KMT2A (0.45) | KMT2AALOX5RAB9ATSHRSMN1; SMN2 | |
| SCHEMBL19353009 | 0.86 | KMT2A (0.51) | KMT2ARAB9AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL21790566 | 0.84 | RAB9A (0.44) | KMT2ARAB9AALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL18893367 | 0.78 | KMT2A (0.49) | KMT2ARAB9AALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL9684758 | 0.76 | KMT2A (0.50) | KMT2AALOX5RAB9AALDH1A1TSHR | |
| SCHEMBL4416421 | 0.76 | KMT2A (0.50) | KMT2AALOX5RAB9AALDH1A1TSHR | |
| SCHEMBL10245099 | 0.76 | KMT2A (0.55) | KMT2ARAB9AALDH1A1TSHRNPC1 | |
| SCHEMBL297237 | 0.75 | ALOX5 (0.53) | KMT2AALOX5RAB9AGAAMEN1 | |
| SCHEMBL430004 | 0.75 | ALOX5 (0.53) | KMT2AALOX5RAB9AGAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | KMT2A 1251/4885ALOX5 1978/4885RAB9A 723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.